Payment overview · 2025
General Payments
$125.61
7 reported records · 5 companies
Healthcare provider profile · identity verified
Kerry Alan Blackham, DO
Allopathic & Osteopathic Physicians|Family Medicine|Geriatric Medicine · PHILIP, SD · NPI 1922014273
Verified facts
What the public records show
CMS Open Payments records show Kerry Alan Blackham, DO received $125.61 in general payments during 2025 across 7 reported records.
AstraZeneca Pharmaceuticals LP accounted for 46.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Mounjaro.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Mounjaro by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $58.67 | 46.7% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $19.41 | 15.4% | 1 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $17.36 | 13.8% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $16.61 | 13.2% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.56 | 10.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $125.61 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $58.67 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $19.41 | 1 | 2025 |
Source payment records
|
|||||
| GRAFIX PL Normalized: grafix pl |
Biological | Smith+Nephew, Inc. | $17.36 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $16.61 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $16.61 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $13.56 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $13.56 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 322 | 50 |
| Furosemide | Furosemide | 273 | 40 |
| Levothyroxine Sodium | Levothyroxine Sodium | 270 | 43 |
| Losartan Potassium | Losartan Potassium | 257 | 53 |
| Tamsulosin Hcl | Tamsulosin Hcl | 238 | 36 |
| Amlodipine Besylate | Amlodipine Besylate | 223 | 43 |
| Sertraline Hcl | Sertraline Hcl | 181 | 28 |
| Potassium Chloride | Potassium Chloride | 180 | 30 |
| Hydrochlorothiazide | Hydrochlorothiazide | 179 | 35 |
| Gabapentin | Gabapentin | 174 | 27 |
| Omeprazole | Omeprazole | 159 | 24 |
| Trazodone Hcl | Trazodone Hcl | 156 | 28 |
| Quetiapine Fumarate | Quetiapine Fumarate | 149 | 20 |
| Eliquis | Apixaban | 145 | 19 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 141 | 37 |
| Prednisone | Prednisone | 135 | 85 |
| Metoprolol Succinate | Metoprolol Succinate | 121 | 30 |
| Metformin Hcl | Metformin Hcl | 117 | 26 |
| Lisinopril | Lisinopril | 109 | 28 |
| Tramadol Hcl | Tramadol Hcl | 109 | 38 |
| Lansoprazole | Lansoprazole | 88 | 14 |
| Carvedilol | Carvedilol | 86 | 14 |
| Montelukast Sodium | Montelukast Sodium | 74 | 11 |
| Simvastatin | Simvastatin | 74 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 72 | suppressed |
| Glipizide | Glipizide | 69 | 11 |
| Pantoprazole Sodium | Pantoprazole Sodium | 69 | 12 |
| Fentanyl | Fentanyl | 68 | 12 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 66 | 16 |
| Azithromycin | Azithromycin | 63 | 54 |
| Spironolactone | Spironolactone | 63 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 58 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 55 | 42 |
| Metoprolol Tartrate | Metoprolol Tartrate | 53 | suppressed |
| Mirtazapine | Mirtazapine | 51 | suppressed |
| Topiramate | Topiramate | 51 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 50 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 49 | 17 |
| Oxycodone Hcl | Oxycodone Hcl | 48 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 48 | suppressed |
| Synthroid | Levothyroxine Sodium | 47 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 46 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 45 | 15 |
| Pregabalin | Pregabalin | 45 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 44 | suppressed |
| Meloxicam | Meloxicam | 44 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 40 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 39 | 26 |
| Jardiance | Empagliflozin | 36 | suppressed |
| Glipizide Er | Glipizide | 35 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 34 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 34 | 26 |
| Baclofen | Baclofen | 32 | suppressed |
| Mounjaro | Tirzepatide | 31 | suppressed |
| Ozempic | Semaglutide | 31 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 31 | suppressed |
| Ezetimibe | Ezetimibe | 29 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 29 | suppressed |
| Allopurinol | Allopurinol | 28 | suppressed |
| Cefdinir | Cefdinir | 28 | 23 |
| Ondansetron Odt | Ondansetron | 28 | 16 |
| Finasteride | Finasteride | 27 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 26 | 14 |
| Atenolol | Atenolol | 26 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 26 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 26 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 25 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 25 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 25 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 25 | suppressed |
| Amoxicillin | Amoxicillin | 24 | 22 |
| Digoxin | Digoxin | 24 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 23 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 23 | suppressed |
| Xarelto | Rivaroxaban | 23 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 23 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 22 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 21 | 11 |
| Brilinta | Ticagrelor | 21 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 20 | 20 |
| Fenofibrate | Fenofibrate | 20 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 20 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 19 | suppressed |
| Entresto | Sacubitril/Valsartan | 19 | suppressed |
| Famotidine | Famotidine | 19 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 19 | suppressed |
| Lorazepam | Lorazepam | 19 | 11 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 18 | suppressed |
| Bumetanide | Bumetanide | 17 | suppressed |
| Dexamethasone | Dexamethasone | 17 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 17 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 16 | suppressed |
| Bupropion Xl | Bupropion Hcl | 16 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 16 | suppressed |
| Azathioprine | Azathioprine | 15 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 15 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 14 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Haloperidol | Haloperidol | 13 | suppressed |
| Latanoprost | Latanoprost | 13 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 13 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 13 | suppressed |
| Multaq | Dronedarone Hcl | 13 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 13 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 12 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 12 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 12 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 11 | suppressed |
| Haloperidol Lactate | Haloperidol Lactate | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 11 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 11 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $125.61 · 7 records | AstraZeneca Pharmaceuticals LP | CAPLYTA, EVENITY, FARXIGA, GRAFIX PL, MOUNJARO, PROLIA, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error